- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03906292
Frontline Asciminib Combination in Chronic Phase CML (CMLXI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Despite the dramatic progress made over the past decade with TKIs in the treatment of CML, allogeneic stem cell transplant remains the only proven curative therapy. To achieve cure or benefit from treatment-free remissions with pharmacologically-based therapies, it is estimated that patients will likely need to achieve a sustained reduction in tumor burden corresponding to a deep molecular response of at least 4 logs (MR4). Currently, only 30.8% of patients achieve a deep molecular response after 12 months of treatment with single agent nilotinib.
The development of the novel and potent BCR-ABL1 allosteric inhibitor, asciminib, presents an opportunity to assess the effect of a different mechanism of inhibition of BCR-ABL1 in the first-line treatment of CML to enhance speed of response and to increase the patient population benefitting from deep molecular response. Dosing a combination of asciminib with an ATP-site inhibitor also has the potential to prevent the emergence of resistance due to point mutations being acquired in one of the binding sites.
The safety, tolerability and pharmacokinetic profile of asciminib as a single agent and in combination with either nilotinib or imatinib or dasatinib was assessed in a phase-I study. At the doses chosen here, all three combination treatments were well tolerated.
Since in all patient cohorts the standard of care therapy will remain the backbone of initial therapy, there is no reason to expect an efficacy problem with the combination therapies.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Aachen, Germany, 52074
- Universitätsklinikum Aachen Medizinische Klinik IV
-
Berlin, Germany, 13353
- Charite Universitätsmeditin Berlin, Campus Virchow Klinikum
-
Bonn, Germany, 53105
- Universitatsklinikum Bonn
-
Bremen, Germany, 28177
- Klinikum Bremen Mitte
-
Chemnitz, Germany, 09113
- Klinikum Chemnitz gGmbH
-
Dresden, Germany, 01307
- Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
-
Dresden, Germany, 01307
- GOKOS GmbH
-
Erlangen, Germany, 91054
- Universitatsklinikum Erlangen
-
Essen, Germany, 45122
- Universitatsklinikum Essen
-
Frankfurt, Germany, 60590
- Universitatsklinikum Frankfurt
-
Freiburg, Germany, 79106
- Universitatsklinikum Freiburg
-
Jena, Germany, 07747
- Universitatsklinikum Jena
-
Leipzig, Germany, 04103
- Universitätsklinikum Leipzig
-
Magdeburg, Germany, 39104
- Gemeinschaftspraxis Dres. Müller/ Kröning/ Jentsch-Ullrich/ Tietze/ Krogel
-
Mainz, Germany, 55131
- Universitätsmedizin der Johannes- Gutenberg Universität Mainz
-
Mannheim, Germany, 68169
- Universitätsmedizin Mannheim
-
Marburg, Germany, 35043
- Universitätsklinikum Giessen und Marburg
-
München, Germany, 81675
- Klinikum rechts der Isar
-
Paderborn, Germany, 33098
- Brüderkrankenhaus St. Josef Paderborn
-
Regensburg, Germany, 93049
- Krankenhaus Barmherzige Bruder Regensburg
-
Ulm, Germany, 89081
- Universitatsklinikum Ulm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of the Ph+ chromosome [t(9;22)(q34;q11)].
- Ph-negative cases or patients with variant translocations who are BCR-ABL1 positive in multiplex PCR 35 will be also considered eligible.
- ECOG performance status of ≤2.
- Age ≥ 18 years old (no upper age limit is given)
- Serum levels of potassium, magnesium, total calcium within the normal limits (≥LLN [lower limit of normal] and ≤ULN [upper limit of normal]). Correction of electrolytes levels with supplements to fulfil enrolment criteria is allowed.
- AST and ALT ≤2.5 x ULN or 5.0 x ULN if considered due to leukemia
- Alkaline phosphatase ≤2.5 x ULN unless considered due to leukemia
- Total bilirubin ≤1.5 x ULN, except known Gilbert disease
- Serum creatinine ≤2 x ULN
- Written informed consent prior to any study procedures being performed.
Exclusion Criteria:
- Allogeneic stem cell transplantation
Known impaired cardiac function, including any of the following:
- Congenital long QT syndrome
- History of or presence of clinically significant ventricular or atrial tachyarrhythmia
- QTc >450 msec on screening ECG
- Myocardial infarction within 12 months prior to starting therapy
- Other clinical significant heart disease (e.g. unstable angina, congestive heart failure)
- Acute or chronic viral hepatitis with moderate or severe hepatic impairment (Child-Pugh scores >6), even if controlled
- Other concurrent uncontrolled medical conditions (e.g., active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol
- Impaired gastrointestinal function or disease that may alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea, malabsorption syndrome, small bowel resection or gastric by-pass surgery)
- Concomitant medications known to be strong inducers or inhibitors of the CYP450 isoenzyme CYP3A4
- Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
- Patients who are pregnant or breastfeeding or women of reproductive potential not employing an effective method of birth control. Women of childbearing potential must have a negative serum pregnancy test within 14 days of study start. Post-menopausal women must be amenorrheic for at least 12 months in order to be considered of non-childbearing potential. Male and female patients must agree to employ an effective method of birth control throughout the study and for up to 2 weeks following discontinuation of study drug
- Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)
- Known serious hypersensitivity reactions to asciminib, imatinib, nilotinib or dasatinib
- Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
- Patients unwilling or unable to comply with the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Asciminib 60mg QD
Standard therapy of Imatinib 400 mg QD and asciminib 60 mg QD
|
Imatinib 400 mg QD and asciminib 60 mg QD
Other Names:
Asciminib 80 mg QD Monotherapy
|
Experimental: Asciminb 20 mg BID
Standard therapy of Nilotinib 300 mg BID and asciminib 20 mg BID
|
Asciminib 80 mg QD Monotherapy
Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD
Other Names:
|
Experimental: Asciminib 40 mg QD
Standard therapy of Nilotinib 300 mg BID and asciminib 40 mg QD
|
Asciminib 80 mg QD Monotherapy
Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD
Other Names:
|
Experimental: Asciminib 80 mg QD
Standard therapy of Dasatinib 100 mg QD and asciminib 80 mg QD
|
Asciminib 80 mg QD Monotherapy
Dasatinib 100 mg QD and asciminib 80 mg QD
Other Names:
|
Experimental: Asciminib 80 mg QD monotherapy
Asciminib 80 mg QD as a single agent
|
Asciminib 80 mg QD Monotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
deep molecular response (Rate of MR4)
Time Frame: at month 12 after Start of Standard-Therapy
|
Achievement of deep molecular response (MR4) throught standardized testing of BCR-ABL-transcript Levels
|
at month 12 after Start of Standard-Therapy
|
deep molecular Response (Rate of MR4.5)
Time Frame: at month 36 after Start of Standard-Therapy
|
Achievement of deep molecular response (MR4.5)
throught standardized testing of BCR-ABL-transcript Levels
|
at month 36 after Start of Standard-Therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
molecular response (MMR and MR4.5)
Time Frame: at and by 6, 12, 18, 24, 36 and 60 months after Start of Therapy
|
Achievement of deep molecular response throught standardized testing of BCR-ABL-transcript levels
|
at and by 6, 12, 18, 24, 36 and 60 months after Start of Therapy
|
Adverse Events
Time Frame: at and by baseline, 3, 6, 12, 15, 18, 21, 24, 36 and 60 months after Start of Therapy
|
Incidence of adverse events grade 1-5 and 3-5
|
at and by baseline, 3, 6, 12, 15, 18, 21, 24, 36 and 60 months after Start of Therapy
|
Progression free survival
Time Frame: at month 60 after Start of Therapy
|
Progression free survival at the end of the study
|
at month 60 after Start of Therapy
|
Overall survival
Time Frame: at month 60 after Start of Therapy
|
Overall survival at the end of the study
|
at month 60 after Start of Therapy
|
Maintenance of MR4.5 during Asciminib-monotherapy
Time Frame: at month 36 and 60 after Start of Therapy
|
Achievement of deep molecular response (MR4.5)
throught standardized testing of BCR-ABL-transcript Levels
|
at month 36 and 60 after Start of Therapy
|
Achievement and durability of treatment-free remission
Time Frame: months 37 and 60 after Start of Therapy
|
Achievement of deep molecular response (MR4) throught standardized testing of BCR-ABL-transcript Levels
|
months 37 and 60 after Start of Therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas Ernst, Prof. Dr., University Hospital Jena
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Micronutrients
- Protein Kinase Inhibitors
- Vitamins
- Vitamin B Complex
- Imatinib Mesylate
- Dasatinib
- Niacinamide
Other Study ID Numbers
- Fascination
- 2018-002256-33 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myeloid Leukemia
-
Newcastle UniversityBristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaboratorsCompletedMyeloid Leukemia, Chronic, Chronic PhaseUnited Kingdom
-
Asan Medical CenterTerminatedLeukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated PhaseKorea, Republic of
-
Bristol-Myers SquibbTerminatedLeukemia, Myeloid, ChronicSweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
-
University of BolognaCompletedMyeloid Leukemia, Chronic, Chronic-PhaseItaly
-
Bristol-Myers SquibbWithdrawnMyeloid Leukemia, Chronic, Chronic-PhaseUnited States
-
PETHEMA FoundationCompleted
-
Fundacion Espanola para la Curacion de la Leucemia...Pfizer; Roche Farma, S.ATerminatedChronic Phase-Chronic Myeloid LeukemiaSpain
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
-
Associazione Italiana Pazienti Leucemia Mieloide...Not yet recruitingChronic Myeloid Leukemia (CML)Italy
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte Corporation; H. Jean Khoury Cure CML ConsortiumRecruitingChronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid LeukemiaUnited States
Clinical Trials on Imatinib
-
Scandinavian Sarcoma GroupCompleted
-
Centre Leon BerardCompletedGastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene MutationFrance
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myeloid LeukemiaChina
-
Sarit AssoulineNovartisRecruitingChronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | Chronic Myeloid Leukemia, BCR/ABL-PositiveCanada
-
M.D. Anderson Cancer CenterNovartisCompletedGastrointestinal Stromal TumorsUnited States
-
Seoul St. Mary's HospitalNovartisUnknownChronic Myeloid LeukemiaKorea, Republic of
-
Novartis PharmaceuticalsCompletedGastrointestinal Stromal TumorsUnited States, France, Belgium, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMelanoma | Skin NeoplasmsUnited States
-
University of Auckland, New ZealandLeukaemia & Blood Cancer New ZealandActive, not recruiting
-
Novartis PharmaceuticalsCompletedPulmonary Arterial HypertensionAustria, Germany, United States, United Kingdom